Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.

•Individuals with certain chronic comorbidities have increased risk of pneumonia.•A pivotal study in older adults found 45.6% PCV13 VE against VT-CAP first episodes.•This post hoc analysis found that at-risk participants had a PCV13 VE of 40.3%.•PCV13 protection persisted over the study follow-up, which averaged 3.95 years.•PCV13 may also be effective in preventing VT-CAP in at-risk younger adults.